Castle Biosciences Inc (CSTL): who owns it and who trades it
As of Nov 16, 2026, CSTL insiders reported 170 open-market sales worth $18.9M and no purchases in the last 12 months, with 83% of the sale value made under pre-set 10b5-1 plans. The largest seller was Derek J Maetzold (Director), with $11.6M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Castle Biosciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CSTL
177 funds and institutions reported CSTL shares worth $696M at the end of Q2 2026, about 94% of the company. The largest holder is BlackRock, Inc. with 10.9%.
Funds and institutions (13F) 94%Everyone else 6%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 3.29M | 10.85% | $78.5M | +10% |
| Rtw Investments, LP | 2.78M | 9.16% | $66.3M | +1% |
| Principal Financial Group Inc | 1.73M | 5.69% | $41.2M | -2% |
| Vanguard Capital Management LLC | 1.23M | 4.04% | $29.3M | +4% |
| Acadian Asset Management LLC | 918,668 | 3.03% | $21.9M | +90% |
| California State Teachers Retirement System | 901,578 | 2.97% | $37.8M | +3177% |
| Vanguard Portfolio Management LLC | 840,785 | 2.77% | $20.1M | -2% |
| Summit Partners Public Asset Management, LLC | 824,872 | 2.72% | $19.7M | -12% |
| State Street Corp | 822,079 | 2.71% | $19.6M | +7% |
| Allianz Asset Management GmbH | 811,324 | 2.67% | $19.9M | No change |
| Geode Capital Management, LLC | 795,912 | 2.62% | $19M | +9% |
| Mackenzie Financial Corp | 793,507 | 2.62% | $18.9M | +971% |
| Dimensional Fund Advisors LP | 791,085 | 2.61% | $18.9M | -24% |
| Jefferies Financial Group Inc. | 647,391 | 2.13% | $15.4M | – |
| Qube Research & Technologies Ltd | 589,300 | 1.94% | $14.1M | +5% |
| AIGH Capital Management LLC | 545,101 | 1.80% | $13M | -8% |
| Renaissance Technologies LLC | 371,200 | 1.22% | $8.9M | -30% |
| Goldman Sachs Group Inc | 358,397 | 1.18% | $8.5M | +5% |
| Point72 Asset Management, L.P. | 357,317 | 1.18% | $8.5M | – |
| Kennedy Capital Management LLC | 348,371 | 1.15% | $8.3M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CSTL insiders reported $0 of open-market purchases and $18.9M of sales. 83% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale | 3,195 | $35.07 | $112K | Form 4 |
| Nov 11, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 2,828 | $35.04 | $99.1K | Form 4 |
| Nov 9, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 3,288 | $32.67 | $107K | Form 4 |
| Nov 2, 2026 | Derek J Maetzold | Director | Sale plan | 7,555 | $36.01 | $272K | Form 4 |
| Nov 2, 2026 | Derek J Maetzold | Director | Sale plan | 2,816 | $36.01 | $101K | Form 4 |
| Nov 2, 2026 | Derek J Maetzold | Director | Sale plan | 2,393 | $36.01 | $86.2K | Form 4 |
| Nov 2, 2026 | Derek J Maetzold | Director | Sale plan | 1,025 | $36.81 | $37.7K | Form 4 |
| Nov 2, 2026 | Derek J Maetzold | Director | Sale plan | 382 | $36.81 | $14.1K | Form 4 |
| Nov 2, 2026 | Derek J Maetzold | Director | Sale plan | 325 | $36.81 | $12K | Form 4 |
| Oct 28, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 1,237 | $35.58 | $44K | Form 4 |
| Oct 28, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 5,341 | $36.62 | $196K | Form 4 |
| Oct 26, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 3,288 | $33.08 | $109K | Form 4 |
| Oct 19, 2026 | Derek J Maetzold | Director | Sale plan | 8,580 | $31.91 | $274K | Form 4 |
| Oct 19, 2026 | Derek J Maetzold | Director | Sale plan | 3,198 | $31.91 | $102K | Form 4 |
| Oct 19, 2026 | Derek J Maetzold | Director | Sale plan | 2,718 | $31.91 | $86.7K | Form 4 |
| Oct 12, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 3,288 | $33.64 | $111K | Form 4 |
| Oct 5, 2026 | Derek J Maetzold | Director | Sale plan | 8,580 | $35.57 | $305K | Form 4 |
| Oct 5, 2026 | Derek J Maetzold | Director | Sale plan | 3,198 | $35.57 | $114K | Form 4 |
| Oct 5, 2026 | Derek J Maetzold | Director | Sale plan | 2,718 | $35.57 | $96.7K | Form 4 |
| Oct 1, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 2,807 | $35.75 | $100K | Form 4 |
| Oct 1, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 1,346 | $36.38 | $49K | Form 4 |
| Sep 30, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 1,034 | $34.20 | $35.4K | Form 4 |
| Sep 29, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 5,543 | $35.50 | $197K | Form 4 |
| Sep 21, 2026 | Derek J Maetzold | Director | Sale plan | 2,718 | $35.33 | $96K | Form 4 |
| Sep 21, 2026 | Derek J Maetzold | Director | Sale plan | 3,198 | $35.33 | $113K | Form 4 |
| Sep 21, 2026 | Derek J Maetzold | Director | Sale plan | 8,580 | $35.33 | $303K | Form 4 |
| Sep 15, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 3,294 | $35.14 | $116K | Form 4 |
| Sep 14, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 3,306 | $32.32 | $107K | Form 4 |
| Sep 11, 2026 | Derek J Maetzold | Director | Sale plan | 8,361 | $32.00 | $268K | Form 4 |
| Sep 11, 2026 | Derek J Maetzold | Director | Sale plan | 3,124 | $32.00 | $100K | Form 4 |
| Sep 11, 2026 | Derek J Maetzold | Director | Sale plan | 2,656 | $32.00 | $85K | Form 4 |
| Sep 11, 2026 | Derek J Maetzold | Director | Sale plan | 71 | $32.78 | $2.3K | Form 4 |
| Sep 11, 2026 | Derek J Maetzold | Director | Sale plan | 83 | $32.78 | $2.7K | Form 4 |
| Sep 11, 2026 | Derek J Maetzold | Director | Sale plan | 223 | $32.78 | $7.3K | Form 4 |
| Sep 1, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 200 | $34.02 | $6.8K | Form 4 |
| Sep 1, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 3,952 | $33.36 | $132K | Form 4 |
| Aug 31, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 1,730 | $32.81 | $56.8K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 2,505 | $33.14 | $83K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 2,129 | $33.14 | $70.6K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 257 | $33.14 | $8.5K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 21 | $33.88 | $711 | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 956 | $33.88 | $32.4K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 209 | $33.88 | $7.1K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 177 | $33.88 | $6K | Form 4 |
| Aug 28, 2026 | Derek J Maetzold | Director | Sale plan | 11,472 | $33.14 | $380K | Form 4 |
| Aug 25, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 9,050 | $35.04 | $317K | Form 4 |
| Aug 25, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale | 7,161 | $34.26 | $245K | Form 4 |
| Aug 25, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale | 5,223 | $34.64 | $181K | Form 4 |
| Aug 24, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale | 12,218 | $33.69 | $412K | Form 4 |
| Aug 17, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 1,730 | $29.59 | $51.2K | Form 4 |
| Aug 14, 2026 | Frank Stokes | CFO | Sale | 24,908 | $29.77 | $742K | Form 4 |
| Aug 14, 2026 | Derek J Maetzold | Director | Sale plan | 1,100 | $30.02 | $33K | Form 4 |
| Aug 14, 2026 | Derek J Maetzold | Director | Sale plan | 2,714 | $30.02 | $81.5K | Form 4 |
| Aug 14, 2026 | Derek J Maetzold | Director | Sale plan | 2,306 | $30.02 | $69.2K | Form 4 |
| Aug 14, 2026 | Derek J Maetzold | Director | Sale plan | 278 | $30.02 | $8.3K | Form 4 |
| Aug 5, 2026 | Derek J Maetzold | Director | Sale plan | 2,546 | $30.68 | $78.1K | Form 4 |
| Aug 5, 2026 | Derek J Maetzold | Director | Sale plan | 556 | $30.68 | $17.1K | Form 4 |
| Aug 5, 2026 | Derek J Maetzold | Director | Sale plan | 473 | $30.68 | $14.5K | Form 4 |
| Aug 4, 2026 | Derek J Maetzold | Director | Sale plan | 11,935 | $31.34 | $374K | Form 4 |
| Aug 4, 2026 | Derek J Maetzold | Director | Sale plan | 4,782 | $31.34 | $150K | Form 4 |
| Aug 4, 2026 | Derek J Maetzold | Director | Sale plan | 4,063 | $31.34 | $127K | Form 4 |
| Aug 4, 2026 | Derek J Maetzold | Director | Sale plan | 2,866 | $30.79 | $88.2K | Form 4 |
| Aug 4, 2026 | Derek J Maetzold | Director | Sale plan | 3,374 | $30.79 | $104K | Form 4 |
| Aug 4, 2026 | Derek J Maetzold | Director | Sale plan | 8,421 | $30.79 | $259K | Form 4 |
| Aug 3, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 1,100 | $30.62 | $33.7K | Form 4 |
| Aug 3, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 3,000 | $29.12 | $87.4K | Form 4 |
| Aug 3, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 4,486 | $30.00 | $135K | Form 4 |
| Aug 3, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 1,730 | $28.25 | $48.9K | Form 4 |
| Aug 3, 2026 | Derek J Maetzold | Director | Sale plan | 4,232 | $30.35 | $128K | Form 4 |
| Aug 3, 2026 | Derek J Maetzold | Director | Sale plan | 10,664 | $30.35 | $324K | Form 4 |
| Aug 3, 2026 | Derek J Maetzold | Director | Sale plan | 3,597 | $30.35 | $109K | Form 4 |
| Jul 31, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 1,891 | $30.26 | $57.2K | Form 4 |
| Jul 31, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 8,149 | $28.84 | $235K | Form 4 |
| Jul 31, 2026 | Tobin W Juvenal | Chief Commercial Officer | Sale plan | 7,270 | $29.58 | $215K | Form 4 |
| Jul 31, 2026 | Derek J Maetzold | Director | Sale plan | 1,690 | $30.15 | $51K | Form 4 |
| Jul 31, 2026 | Derek J Maetzold | Director | Sale plan | 6,480 | $30.15 | $195K | Form 4 |
| Jul 31, 2026 | Derek J Maetzold | Director | Sale plan | 1,983 | $30.15 | $59.8K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 43 | $25.06 | $1.1K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 10 | $25.06 | $251 | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 5,982 | $24.13 | $144K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 1,307 | $24.13 | $31.5K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 1,110 | $24.13 | $26.8K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 268 | $24.13 | $6.5K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 232 | $25.06 | $5.8K | Form 4 |
| Jul 27, 2026 | Derek J Maetzold | Director | Sale plan | 50 | $25.06 | $1.3K | Form 4 |
| Jul 14, 2026 | Derek J Maetzold | Director | Sale plan | 550 | $22.92 | $12.6K | Form 4 |
| Jul 14, 2026 | Derek J Maetzold | Director | Sale plan | 1,357 | $22.92 | $31.1K | Form 4 |
| Jul 14, 2026 | Derek J Maetzold | Director | Sale plan | 278 | $22.92 | $6.4K | Form 4 |
| Jul 14, 2026 | Derek J Maetzold | Director | Sale plan | 1,153 | $22.92 | $26.4K | Form 4 |
| Jul 1, 2026 | Derek J Maetzold | Director | Sale plan | 1,357 | $24.29 | $33K | Form 4 |
| Jul 1, 2026 | Derek J Maetzold | Director | Sale plan | 1,153 | $24.29 | $28K | Form 4 |
| Jul 1, 2026 | Derek J Maetzold | Director | Sale plan | 278 | $24.29 | $6.8K | Form 4 |
| Jul 1, 2026 | Derek J Maetzold | Director | Sale plan | 6,214 | $24.29 | $151K | Form 4 |
| Jul 1, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 8,186 | $24.40 | $200K | Form 4 |
| Jul 1, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 400 | $24.78 | $9.9K | Form 4 |
| Jun 16, 2026 | Kristen M Oelschlager | Chief Operating Officer | Sale plan | 8,587 | $20.71 | $178K | Form 4 |
| Jun 15, 2026 | Derek J Maetzold | Director | Sale plan | 550 | $20.66 | $11.4K | Form 4 |
| Jun 15, 2026 | Derek J Maetzold | Director | Sale plan | 1,357 | $20.66 | $28K | Form 4 |
| Jun 15, 2026 | Derek J Maetzold | Director | Sale plan | 1,153 | $20.66 | $23.8K | Form 4 |
| Jun 15, 2026 | Derek J Maetzold | Director | Sale plan | 278 | $20.66 | $5.7K | Form 4 |
Latest 100 of 170 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Derek J Maetzold | Pres. & Chief Exec. Officer, Director | – | $11.6M | Nov 2, 2026 |
| Tobin W Juvenal | Chief Commercial Officer | – | $3.5M | Nov 11, 2026 |
| Kristen M Oelschlager | Chief Operating Officer | – | $2.4M | Oct 1, 2026 |
| Frank Stokes | Chief Financial Officer | – | $1.3M | Aug 14, 2026 |
| G Bradley Cole | Director | – | $211K | Mar 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CSTL short interest
Moderate short interest. 6.8% of CSTL shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 49%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.11M CSTL shares were sold short, 6.8% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 347,929 shares, buying them all back would take about 6.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.11M | 6.84% | +5% | 347,929 | 6.1 |
| Oct 15, 2026 | 2.02M | 6.60% | +1% | 337,053 | 6.0 |
| Sep 30, 2026 | 2.00M | 6.55% | +5% | 419,633 | 4.8 |
| Sep 15, 2026 | 1.90M | 6.22% | -4% | 257,937 | 7.4 |
| Aug 31, 2026 | 1.98M | 6.47% | +13% | 391,437 | 5.0 |
| Aug 14, 2026 | 1.75M | 5.74% | +12% | 477,095 | 3.7 |
| Jul 31, 2026 | 1.56M | 5.11% | +10% | 491,979 | 3.2 |
| Jul 15, 2026 | 1.42M | 4.69% | -5% | 251,097 | 5.7 |
| Jun 30, 2026 | 1.49M | 4.92% | +0% | 469,005 | 3.2 |
| Jun 15, 2026 | 1.49M | 4.90% | No change | 284,222 | 5.2 |
| May 29, 2026 | 1.48M | 4.90% | +5% | 393,031 | 3.8 |
| May 15, 2026 | 1.42M | 4.67% | -1% | 633,871 | 2.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Castle Biosciences company events
Castle Biosciences filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- May 29, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 13, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Castle Biosciences financials
Famous investors that hold CSTL
4 of the 50 well-known investors we track reported holding CSTL in their latest 13F filing. The largest position is Israel Englander's, worth $17.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 495,633 | $17.6M | 0.0% | +141% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 322,400 | $11.5M | 0.0% | -13% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 300,799 | $10.7M | 0.0% | +13% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 53,035 | $1.9M | 0.0% | +267% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CSTL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 29, 2026 | PRINCIPAL GLOBAL INVESTORS | 13G/A | 4.9% |
| Oct 29, 2026 | PRINCIPAL GLOBAL INVESTORS | 13G/A | 4.9% |
Questions about Castle Biosciences Inc (CSTL) stock
Who owns the most CSTL stock?
The largest reported owner of Castle Biosciences Inc (CSTL) is BlackRock, Inc., with 10.9% of the company. In total, 177 funds and institutions reported holding CSTL at the end of Q2 2026, together about 94% of the shares. See the largest owners.
Are CSTL insiders buying or selling?
In the last 12 months, CSTL insiders reported no open-market purchases and 170 sales worth $18.9M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in CSTL?
As of Oct 30, 2026, 2.11M CSTL shares were sold short, 6.8% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 347,929 shares, buying them all back would take about 6.1 trading days (days to cover). See the history.
Which famous investors hold CSTL?
4 of the 50 well-known investors we track reported CSTL in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $17.6M. See all holders.
Executive pay
Castle Biosciences's chief executive was paid a total of $6.8M for the year ended Dec 31, 2025, down 2% from $6.9M the year before. In the last 12 months, Castle Biosciences's executives and directors bought no stock on the open market and sold $18.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.